The global ferritin testing market size is expected to reach USD 1.46 billion by 2030, registering a CAGR of 8.0% from 2025 to 2030. The market is growing significantly due to the global prevalence of iron deficiency anemia. According to the World Health Organization (WHO), anemia affects over 1.9 billion people, with iron deficiency being a leading cause. This growing burden, particularly among women, children, and the elderly, is driving the demand for ferritin tests to monitor iron levels. For instance, in India, government initiatives like the Anemia Mukt Bharat campaign emphasize the importance of early anemia diagnosis, boosting the adoption of ferritin testing.
Technological innovations in diagnostics are a key driver of the market. Automated laboratory systems and point-of-care (POC) devices are enabling faster and more accurate ferritin measurements. Companies like Roche and Abbott have introduced advanced immunoassay-based systems that provide precise results with minimal sample volume. For instance, Roche's Elecsys ferritin test is widely used in hospitals and diagnostic labs for efficient anemia management, streamlining workflows, and reducing turnaround times.
Rising awareness of the importance of early diagnosis and preventive healthcare fuels the demand for ferritin testing. Educational campaigns and public health initiatives in regions like Europe and North America encourage routine screening for iron deficiency, particularly for at-risk groups such as pregnant women and children. In the U.S., the Centers for Disease Control and Prevention (CDC) recommend regular anemia screenings for infants and women of childbearing age, contributing to the steady market growth. Emerging economies in Asia Pacific, Latin America, and Africa are witnessing rapid market growth due to improved healthcare infrastructure and increased access to diagnostic services. For example, in China, the government’s focus on maternal and child health has led to the widespread adoption of ferritin tests in routine prenatal checkups. Similarly, in Brazil, expanding healthcare access through public programs like SUS (Sistema Único de Saúde) has boosted the use of ferritin tests for anemia diagnosis.
Leading companies in the market, such as Abbott, Siemens Healthineers, and bioMérieux, are pivotal in driving growth. These players are investing in research and development to introduce innovative testing solutions. For example, Siemens Healthineers offers advanced ferritin assays compatible with their Atellica Solution platforms, which integrate seamlessly into hospital laboratories. In addition, collaborations between diagnostic companies and governments, such as partnerships for anemia screening programs, are further expanding the market’s reach. Some of the key players in the market are BioMrieux, Humankind Ventures Ltd, Aviva Systems Biology Corporation, Abnova Corporation, and Randox Laboratories Ltd. These players are involved in various strategic initiatives, such as product launches and approvals, to cater to a global clientele.
This product will be delivered within 1-3 business days.
Technological innovations in diagnostics are a key driver of the market. Automated laboratory systems and point-of-care (POC) devices are enabling faster and more accurate ferritin measurements. Companies like Roche and Abbott have introduced advanced immunoassay-based systems that provide precise results with minimal sample volume. For instance, Roche's Elecsys ferritin test is widely used in hospitals and diagnostic labs for efficient anemia management, streamlining workflows, and reducing turnaround times.
Rising awareness of the importance of early diagnosis and preventive healthcare fuels the demand for ferritin testing. Educational campaigns and public health initiatives in regions like Europe and North America encourage routine screening for iron deficiency, particularly for at-risk groups such as pregnant women and children. In the U.S., the Centers for Disease Control and Prevention (CDC) recommend regular anemia screenings for infants and women of childbearing age, contributing to the steady market growth. Emerging economies in Asia Pacific, Latin America, and Africa are witnessing rapid market growth due to improved healthcare infrastructure and increased access to diagnostic services. For example, in China, the government’s focus on maternal and child health has led to the widespread adoption of ferritin tests in routine prenatal checkups. Similarly, in Brazil, expanding healthcare access through public programs like SUS (Sistema Único de Saúde) has boosted the use of ferritin tests for anemia diagnosis.
Leading companies in the market, such as Abbott, Siemens Healthineers, and bioMérieux, are pivotal in driving growth. These players are investing in research and development to introduce innovative testing solutions. For example, Siemens Healthineers offers advanced ferritin assays compatible with their Atellica Solution platforms, which integrate seamlessly into hospital laboratories. In addition, collaborations between diagnostic companies and governments, such as partnerships for anemia screening programs, are further expanding the market’s reach. Some of the key players in the market are BioMrieux, Humankind Ventures Ltd, Aviva Systems Biology Corporation, Abnova Corporation, and Randox Laboratories Ltd. These players are involved in various strategic initiatives, such as product launches and approvals, to cater to a global clientele.
Ferritin Testing Market Report Highlights
- Based on product, reagent accounted for the largest revenue share of 45.27% in 2024. The market is being propelled by the growing adoption of immunoassay-based diagnostic techniques like ELISA and chemiluminescent immunoassays, which depend on high-quality reagents for precise and sensitive ferritin measurement. For example, the increasing use of monoclonal antibodies in reagent formulations enhances the specificity and reliability of tests. Companies such as Thermo Fisher Scientific and Roche Diagnostics are driving innovation by developing reagents optimized for automated platforms, further accelerating market expansion. Moreover, the recurring demand for reagents ensures steady revenue, particularly in large diagnostic laboratories and hospitals
- Based on application, anemia dominated the market and accounted for the largest share of 41.47% in 2024. Anemia, affecting one-fourth of the global population, is becoming increasingly common among women, expectant mothers, young girls, and children under 5. By 2021, an estimated 1.92 billion people were living with anemia, a rise of 420 million cases over the last 30 years. This surge is attributed to factors like poor nutrition, chronic illnesses, and limited healthcare access, particularly in developing regions. The growing demand for anemia diagnostics and treatments is driving market growth. Furthermore, the expansion of the global testing market, especially in point-of-care and home-testing devices, is expected to boost this growth, offering more accessible solutions for anemia detection and management
- Based on end use, hospitals dominated end use with the largest market share of 56.32% in 2024. The market growth is fueled by factors such as increasing patient volumes, advancements in medical technology, and the rising demand for specialized treatments. In addition, the expansion of healthcare infrastructure, particularly in emerging economies, plays a significant role in driving this growth. Hospitals are progressively adopting advanced diagnostic tools, including rapid testing devices, to enhance patient outcomes and optimize operational efficiency. These developments are creating a robust demand for innovative solutions in the healthcare sector
- North America dominated the global market, primarily due to the increasing prevalence of iron deficiency anemia and related conditions. Greater awareness of the importance of early diagnosis and monitoring of iron levels is fueling this trend. The aging population and the rising incidence of chronic diseases, such as kidney disease and cancer, which impact iron metabolism, are also driving demand for ferritin tests. Furthermore, advancements in diagnostic technologies, including point-of-care testing and lab-based solutions, are improving accessibility and efficiency, contributing to the market's expansion in the region.
- The Asia Pacific region is expected to witness the fastest growth with a CAGR of 9.23% over the forecast period from 2025 to 2030 due to the presence of manufacturers with innovative devices coupled with accelerated diagnostic research capabilities
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Product Business Analysis
Chapter 5. Application Business Analysis
Chapter 6. End Use Business Analysis
Chapter 7. Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Eurolyser Diagnostica GmbH
- Cortez Diagnostics Inc
- Pointe Scientific, Inc
- bioMrieux
- Humankind Ventures Ltd
- Aviva Systems Biology Corporation
- Abnova Corporation
- Cosmic Scientific Technologies
- CTK Biotech, Inc
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | January 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 0.91 Billion |
| Forecasted Market Value ( USD | $ 1.46 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
